Inozyme Pharma, Inc. financial data

Symbol
INZY on Nasdaq
Location
321 Summer Street, Suite 400, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 460 % -66.9%
Debt-to-equity 93.9 % +136%
Return On Equity -160 % -172%
Return On Assets -82.5 % -96.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.2M shares +3.86%
Common Stock, Shares, Outstanding 64.5M shares +4.29%
Entity Public Float 199M USD -0.06%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 64.3M shares +4.06%
Weighted Average Number of Shares Outstanding, Diluted 64.3M shares +4.06%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 84.5M USD +36.1%
General and Administrative Expense 21M USD +7.45%
Operating Income (Loss) -107M USD -31.6%
Nonoperating Income (Expense) 657K USD -85.4%
Net Income (Loss) Attributable to Parent -107M USD -38.4%
Earnings Per Share, Basic -2 USD/shares -24.4%
Earnings Per Share, Diluted -2 USD/shares -24.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.8M USD +25.4%
Cash, Cash Equivalents, and Short-term Investments 84.8M USD -49%
Assets, Current 93.6M USD -46.3%
Property, Plant and Equipment, Net 608K USD -53.8%
Operating Lease, Right-of-Use Asset 410K USD -58.7%
Assets 95.2M USD -46.2%
Accounts Payable, Current 3.67M USD +69.4%
Employee-related Liabilities, Current 3.67M USD -4.48%
Accrued Liabilities, Current 12.7M USD +36.9%
Liabilities, Current 42.8M USD +245%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 63.4M USD +9.05%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5K USD +95.2%
Retained Earnings (Accumulated Deficit) -416M USD -34.5%
Stockholders' Equity Attributable to Parent 31.8M USD -73.2%
Liabilities and Equity 95.2M USD -46.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.1M USD -18.8%
Net Cash Provided by (Used in) Financing Activities 228K USD +43.4%
Net Cash Provided by (Used in) Investing Activities 33.7M USD +224%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 64.5M shares +4.29%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 125M USD +41%
Deferred Tax Assets, Gross 126M USD +40.5%
Operating Lease, Liability 669K USD +123%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -107M USD -38.1%
Lessee, Operating Lease, Liability, to be Paid 684K USD -59.9%
Property, Plant and Equipment, Gross 3.94M USD +1.52%
Operating Lease, Liability, Current 669K USD -28.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 944K USD -7.09%
Lessee, Operating Lease, Liability, to be Paid, Year One 944K USD -7.09%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15K USD
Deferred Tax Assets, Operating Loss Carryforwards 52.8M USD +22.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 300K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 154K USD -62.4%
Share-based Payment Arrangement, Expense 8.11M USD +22.2%
Interest Expense 1.4M USD +80.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%